Assessing Tenapanor as a Treatment of CF-related Constipation.

NCT06810167

Status	RECRUITING
Phase	Phase 3
Sponsor	Massachusetts General Hospital
Enrollment	25 participants

Key Eligibility Criteria

Inclusion (11)

- Having confirmed cystic fibrosis (either by sweat chloride or genetic testing)
- Meeting criteria for CFrC
- Must include 2 of the following, with or without abdominal pain for at least 3 months, with symptom onset at least 6-months prior:
- Straining in at least 25% of defecations
- Bristol Stool Scale 1-2 more than 25% of defecations (change in stool form)

... and 6 more (see full listing online)

Exclusion (7)

- Use of any antibiotic to treat infection within the 4-weeks prior to study initiation (stable azithromycin dosed 3-times weekly for lung function is to be allowed)
- Inability to discontinue standing bowel regimen (including fiber, stool softener, as well as either osmotic or stimulant laxative, pro-kinetic serotonergic agents, or other therapy) 2-weeks prior to study drug initiation (with ability to use osmotic laxative therapy as rescue therapy only).
- Severe CFrC as determined by study team
- Prior tenapanor usage
- Hospitalization within 4-weeks prior to study initiation.

... and 2 more (see full listing online)

Locations (1 total)

Massachusetts General Hospital, Boston, Massachusetts, United States